Novavax (NASDAQ:NVAX) shares gapped down prior to trading on Friday . The stock had previously closed at $1.86, but opened at $1.81. Novavax shares last traded at $1.82, with a volume of 3091683 shares changing hands.
A number of research analysts recently commented on NVAX shares. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price target on shares of Novavax in a research note on Monday, December 18th. Citigroup lowered shares of Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research note on Tuesday, December 19th. BidaskClub upgraded shares of Novavax from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. B. Riley set a $2.25 price target on shares of Novavax and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, S&P Equity Research decreased their price target on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Novavax currently has an average rating of “Hold” and an average target price of $3.43.
The stock has a market capitalization of $721.24, a PE ratio of -2.89 and a beta of 2.38. The company has a current ratio of 2.76, a quick ratio of 2.76 and a debt-to-equity ratio of -3.12.
Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). The business had revenue of $10.40 million for the quarter, compared to analysts’ expectations of $7.98 million. During the same quarter in the previous year, the firm posted ($0.21) EPS. The firm’s quarterly revenue was up 92.6% on a year-over-year basis. equities research analysts forecast that Novavax will post -0.57 earnings per share for the current year.
Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of Novavax by 17.9% during the 4th quarter. Geode Capital Management LLC now owns 2,945,721 shares of the biopharmaceutical company’s stock worth $3,652,000 after purchasing an additional 446,318 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Novavax by 3.9% during the 4th quarter. Renaissance Technologies LLC now owns 2,815,565 shares of the biopharmaceutical company’s stock worth $3,491,000 after acquiring an additional 105,611 shares during the period. Deutsche Bank AG lifted its holdings in shares of Novavax by 6.3% during the 4th quarter. Deutsche Bank AG now owns 2,567,169 shares of the biopharmaceutical company’s stock worth $3,182,000 after acquiring an additional 152,974 shares during the period. Rock Springs Capital Management LP lifted its holdings in shares of Novavax by 143.9% during the 4th quarter. Rock Springs Capital Management LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 1,180,000 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Novavax by 17.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,443,013 shares of the biopharmaceutical company’s stock worth $1,790,000 after acquiring an additional 217,995 shares during the period. Hedge funds and other institutional investors own 36.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/04/13/novavax-nvax-shares-gap-down-to-1-81.html.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.